(FULC) Fulcrum Therapeutics - Ratings and Ratios

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for genetically defined diseases with high unmet medical needs. The company focuses on advancing treatments for rare and debilitating conditions, leveraging its expertise in small molecule therapeutics and fetal hemoglobin induction.

Its lead product candidate, losmapimod, is a small molecule inhibitor currently in Phase III clinical trials for the treatment of facioscapulohumeral muscular dystrophy (FSHD), a rare genetic disorder characterized by progressive muscle weakness and degeneration. The company is also developing pociredir, a fetal hemoglobin inducer, which is in Phase I clinical trials for the treatment of sickle cell disease and beta-thalassemia, severe hematologic disorders requiring innovative therapeutic approaches.

Fulcrum has established strategic collaborations to expand its pipeline. It partners with Acceleron Pharma Inc. to identify targets in pulmonary diseases, MyoKardia, Inc. to develop therapies for genetic cardiomyopathies, and Sanofi to co-develop and commercialize losmapimod for FSHD. These collaborations underscore its commitment to addressing a broad range of rare and serious diseases, including neuromuscular, muscular, CNS, and hematologic disorders.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Fulcrum Therapeutics operates at the intersection of genetics and drug development, aiming to deliver transformative therapies for patients with limited treatment options.

Ticker Symbol: FULC Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Pharmaceuticals

Average Volume 20d: 400301 Last Price: 3.24 SMA 20: 3.67 SMA 50: 4.09 SMA 200: 5.54 ATR: 0.26

Market Cap: 181.91M USD P/E: 0.00 P/E Forward: 0.00 P/B: 0.74 P/S: 2.27 RoE: -4.00

3-Month Forecast: Based on technical and fundamental analysis, FULC is expected to face headwinds in the near term. The stock is trading below its SMA20 and SMA50, indicating bearish momentum. However, the relatively low ATR suggests moderate volatility. Fundamentally, the negative RoE and low P/B ratio highlight challenges in valuation and profitability. Short-term price stabilization is possible if the company demonstrates progress in its clinical pipeline or announces favorable collaborations.